BI signs KRAS deal with India's Lupin, as pharma awaits key ...

Boehringer Ingelheim has signed a deal with India’s Lupin to develop and market a potential cancer drug targeting tumours driven by the KRAS mutation.

AZ gets China nod for Tagrisso in first-line lung cancer

Immunicum shares fall despite “fantastic” kidney cancer data

Tecentriq beats rivals to EU breast cancer market

AbbVie axes multi-billion cancer flop Rova-T after another t...

AbbVie has axed its troubled lung cancer drug Rova-T, after another trial failure from the drug that is turning out to be an expensive flop, costing almost $10 billion so far.

Celgene strikes $1.5bn cell therapy deal with Immatics